| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
15,280,000 |
| Market
Cap: |
98.56(M) |
| Last
Volume: |
1,505,916 |
Avg
Vol: |
1,501,805 |
| 52
Week Range: |
$2.25 - $8.09 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.6 |
| Insider 6 Months : 11.3 |
| Insider 3/6 Months : 20.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Co.'s primary product candidate, the HEPZATO™ KIT (melphalan hydrochloride for injection/hepatic delivery system) (HEPZATO), is a drug/device combination product. HEPZATO is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, Co.'s commercial product is a stand-alone medical device having the same device components as the HEZPATO but without the melphalan hydrochloride and is approved for sale under the trade name CHEMOSAT® Hepatic Delivery System for Melphalan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
53,764 |
127,764 |
382,819 |
547,434 |
| Total Buy Value |
$200,002 |
$419,962 |
$1,081,809 |
$1,686,989 |
| Total People Bought |
2 |
4 |
8 |
9 |
| Total Buy Transactions |
2 |
4 |
10 |
15 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Aharon Gil |
Director |
– • – |
2024-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
991,615 |
2,681,271 |
|
- |
|
| Aharon Gil |
Director |
– • – |
2024-04-18 |
4 |
OE |
$6,199.46 |
$2,147,483,647 |
I/I |
619,946 |
2,681,271 |
|
- |
|
| Aharon Gil |
Director |
– • – |
2024-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
991,615 |
2,763,468 |
|
- |
|
| Aharon Gil |
Director |
– • – |
2024-04-18 |
4 |
OE |
$6,199.46 |
$2,147,483,647 |
I/I |
619,946 |
2,763,468 |
|
- |
|
| Aharon Gil |
Director |
– • – |
2024-04-18 |
4/A |
A |
$0.00 |
$0 |
I/I |
991,615 |
2,681,271 |
|
- |
|
| Aharon Gil |
Director |
– • – |
2024-04-18 |
4/A |
OE |
$0.01 |
$6,199 |
I/I |
619,946 |
2,681,271 |
|
- |
|
| Salamon Steven A J |
Director |
– • – |
2024-04-18 |
4 |
OE |
$6,199.46 |
$2,147,483,647 |
I/I |
619,946 |
2,732,586 |
|
- |
|
| Salamon Steven A J |
Director |
– • – |
2024-04-18 |
4 |
A |
$0.00 |
$0 |
I/I |
991,615 |
2,732,586 |
|
- |
|
| Salamon Steven A J |
Director |
– • – |
2024-04-18 |
4/A |
A |
$0.00 |
$0 |
I/I |
991,615 |
2,732,586 |
|
- |
|
| Salamon Steven A J |
Director |
– • – |
2024-04-18 |
4/A |
OE |
$0.01 |
$6,199 |
I/I |
619,946 |
2,732,586 |
|
- |
|
| Salamon Steven A J |
Director |
– • – |
2024-03-19 |
4 |
B |
$3.72 |
$100,001 |
D/D |
26,882 |
1,121,025 |
2.39 |
65% |
|
| Aharon Gil |
Director |
– • – |
2024-03-19 |
4 |
B |
$3.72 |
$100,001 |
D/D |
26,882 |
1,069,710 |
2.39 |
65% |
|
| Hoffman David L. |
GENL COUNSEL, CCO & SECY |
• – – |
2024-03-19 |
4 |
A |
$3.72 |
$74,999 |
D/D |
20,161 |
74,330 |
|
- |
|
| Pennell Sandra |
SVP OF FINANCE, PFO AND PAO |
• – – |
2024-03-19 |
4 |
A |
$3.72 |
$99,997 |
D/D |
26,881 |
61,052 |
|
- |
|
| Muir Kevin |
GM INTERVENTIONAL ONCOLOGY |
• – – |
2024-03-19 |
4 |
A |
$3.72 |
$50,001 |
D/D |
13,441 |
18,582 |
|
- |
|
| Vukovic Vojo |
CHIEF MEDICAL OFFICER |
• – – |
2024-03-19 |
4 |
A |
$3.72 |
$100,001 |
D/D |
26,882 |
126,882 |
|
- |
|
| Michel Gerard J |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-03-19 |
4 |
A |
$3.72 |
$150,002 |
D/D |
40,323 |
302,668 |
|
- |
|
| Vukovic Vojo |
Chief Medical Officer |
• – – |
2023-12-12 |
4 |
B |
$3.00 |
$120,000 |
D/D |
40,000 |
100,000 |
2.74 |
74% |
|
| Michel Gerard J |
Chief Executive Officer |
• • – |
2023-12-08 |
4 |
B |
$2.94 |
$99,960 |
D/D |
34,000 |
262,345 |
2.81 |
85% |
|
| Aharon Gil |
Director |
– • – |
2023-11-17 |
4 |
B |
$2.40 |
$240,410 |
I/I |
100,000 |
1,038,828 |
2.1 |
96% |
|
| Pennell Sandra |
SVP of Finance, PFO and PAO |
• – – |
2023-11-17 |
4 |
B |
$2.43 |
$72,900 |
D/D |
30,000 |
30,000 |
2.74 |
96% |
|
| Vukovic Vojo |
Chief Medical Officer |
• – – |
2023-11-16 |
4 |
B |
$2.48 |
$148,800 |
D/D |
60,000 |
60,000 |
2.74 |
93% |
|
| Hoffman David L. |
See Remarks |
• – – |
2023-11-16 |
4 |
B |
$2.48 |
$99,200 |
D/D |
40,000 |
40,000 |
2.74 |
93% |
|
| Purpura John |
Chief Operating Officer |
• – – |
2023-10-13 |
4 |
B |
$3.44 |
$49,897 |
D/D |
14,505 |
41,526 |
2.74 |
25% |
|
| Sylvester John Richard |
Director |
– • – |
2023-08-21 |
4 |
B |
$4.80 |
$50,640 |
D/D |
10,550 |
10,550 |
2.39 |
-18% |
|
370 Records found
|
|
Page 1 of 15 |
|
|
0.28 (4.16%) 
